TCGA-22-5479-01A-31R-1949-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.580
- MYC_TARGETS_V2+0.580
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.490
- MTORC1_SIGNALING+0.440
- OXIDATIVE_PHOSPHORYLATION+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.340
- DNA_REPAIR+0.210
- UV_RESPONSE_UP+0.210
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.330
- IL6_JAK_STAT3_SIGNALING-0.270
- ANGIOGENESIS-0.260
- COMPLEMENT-0.260
- NOTCH_SIGNALING-0.260
- TGF_BETA_SIGNALING-0.260
- BILE_ACID_METABOLISM-0.250
- ALLOGRAFT_REJECTION-0.230
- INTERFERON_ALPHA_RESPONSE-0.230
- PROTEIN_SECRETION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932827 | — | — | 0.899 |
| 2 | TCGA-77-7139-01A-11R-2045-07 | — | cohortSQ2 | 0.877 |
| 3 | C3N-01411 | — | cohortSQ2 | 0.865 |
| 4 | SRR6013575 | — | cohortSQ2 | 0.865 |
| 5 | TCGA-85-8277-01A-11R-2296-07 | — | cohortSQ2 | 0.859 |
| 6 | TCGA-77-8144-01A-11R-2247-07 | — | cohortSQ1 | 0.848 |
| 7 | TCGA-NC-A5HN-01A-11R-A26W-07 | — | cohortSQ2 | 0.848 |
| 8 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.847 |
| 9 | C3N-02434 | — | cohortSQ2 | 0.847 |
| 10 | TCGA-68-7755-01A-11R-2125-07 | — | cohortSQ2 | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.410 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |